Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 3600 Green Ct Ste 350 ANN ARBOR MI 48105-2440 |
Tel: | 1-310-6917100 |
Website: | https://www.endrainc.com |
IR: | See website |
Key People | ||
Francois Roger Michelon Chairman of the Board, Chief Executive Officer | Irina Pestrikova Senior Director of Finance | Michael Milos Thornton Chief Technology Officer |
Business Overview |
ENDRA Life Sciences Inc. develops technology for increasing the capabilities of clinical diagnostic ultrasound to broaden patient access to the diagnosis and treatment of various medical conditions in circumstances where other diagnostic technologies are unavailable or impractical. The Company has developed a technology platform, Thermo Acoustic Enhanced Ultrasound (TAEUS), which is intended to enhance the capability of clinical ultrasound technology and support the diagnosis and treatment of various other medical conditions. Its TAEUS technology platform application focuses on quantifying fat in the liver and staging the progression of non-alcoholic fatty liver disease (NAFLD), which, if untreated, can progress to non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and liver cancer. The Company's TAEUS platform has various clinical applications, such as tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. |
Financial Overview |
For the nine months ended 30 September 2023, ENDRA Life Sciences Inc revenues was not reported. Net loss decreased 13% to $8.6M. Lower net loss reflects Other income (expense) increase from $45K (expense) to $462K (income), Research and development decrease of 10% to $4.4M (expense), Other SGA decrease of 39% to $673K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$3.58 to -$1.76. |
Employees: | 21 as of Dec 31, 2022 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $3.63M as of Sep 30, 2023 |
Annual revenue (TTM): | $0.00M as of Sep 30, 2023 |
EBITDA (TTM): | -$12.24M as of Sep 30, 2023 |
Net annual income (TTM): | -$11.89M as of Sep 30, 2023 |
Free cash flow (TTM): | -$10.53M as of Sep 30, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 8,454,922 as of Nov 14, 2023 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |